DRUGS MADE IN AMERICA ACQUISITION II CORP.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $4.4M | $4.3M | $-46.2K | $-38.1K | $-59.3K |
| Depreciation & Amortization | — | — | — | — | — |
| Depreciation | — | — | — | — | — |
| Amortization | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — |
| Net Cash from Operating Activities | $-172.7K | $-102.5K | $-690.7K | $-2.6K | $-10.0K |
| Investing Activities | |||||
| Capital Expenditures | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — |
| Financing Activities | |||||
| Dividends Paid | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — |
| Net Cash from Financing Activities | — | $450.0K | — | — | — |
| Net Change in Cash | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — |